Filtered By:
Condition: Pulmonary Hypertension
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 621 results found since Jan 2013.
Clinical value of echocardiography in evaluating hemodynamics and right ventricular function in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty
CONCLUSIONS: The findings show that a single BPA procedure significantly improves RV volume load and reduces the pulmonary blood pressure in CTEPH patients in the short-term. However, BPA does not improve RV systolic function 24 hours after the procedure. The results indicate that evaluation of RV structural and function with echocardiography is an effective approach for non-invasive monitoring of patient status after BPA.PMID:35693626 | PMC:PMC9186241 | DOI:10.21037/jtd-21-1536
Source: Journal of Thoracic Disease - June 13, 2022 Category: Respiratory Medicine Authors: Jiaxin Chen Shangwei Ding Chenkai Zhang Rifei Li Wenliang Guo Chen Hong Qing Tang Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Drugs of Misuse: Focus on Vascular Dysfunction
Can J Cardiol. 2022 Apr 21:S0828-282X(22)00261-6. doi: 10.1016/j.cjca.2022.04.011. Online ahead of print.ABSTRACTCommon drugs of misuse, including cannabis, opioids, stimulants, alcohol, and anabolic steroids, have strikingly disparate acute and chronic vascular effects, leading to a wide range of clinical cardiovascular presentations. Acute cannabis smoking has been associated with increased risk for myocardial infarction and ischemic stroke in otherwise healthy young people. However, it remains uncertain if people who exclusively smoke cannabis have increased risk for accelerated atherosclerosis similar to that found in ...
Source: Atherosclerosis - April 24, 2022 Category: Cardiology Authors: Holly R Middlekauff Ziva D Cooper Sasha B Strauss Source Type: research
